Event Date:
20 May 2009 -
20 May 2009
Geography:
North America
Country: USA
City: Georgia
Contact: Connie Ness
Email: connie.ness@scotent.co.uk
Event Date: Wednesday, 20 May 2009
Event Time: 10:00 - 11:30
Location: B304, Georgia World Congress Center, Georgia, USA
There has been a great deal of interest in the potential of the Ubiquitin Proteasome System (UPS), which many consider to be the next step along from the kinase research. Kinases are currently one of the top targets for the Pharmaceutical industry with up to 30 per cent of drug discovery budgets being on this target class. The broader roles of the UPS in disease is driving increased academic and industrial attention, and with the approval of the drug Velcase for treatment of multiple myeloma, we now have proof of principal and the potential for investment in many new drugs. The panel will discuss some of their business models and how they plan to fast-track through momentum gained from kinase drug discovery towards commercial endpoints. They will also discuss the attractiveness of the UPS market to investors. Part of BIO 2009 event.
Speakers:
- Mike Tyers, PhD - Professor of Systems Biology, Director of the Scottish Universities Life Science Alliance (SULSA)
- Philip Cohen, FRSC - Professor Sir, Director of MRC Protein Phoshorylation Unit and Scottish Institute for Cell Signalling
- Giovanni Ferrara, MBA - Advisor to ITI Life Sciences
- Sheridan Snyder, LLB - Chief Executive Officer, BioCatalyst International
- Mark Manfredi, PhD - Director of Cancer Pharmacology, Millennium: The Takeda Oncology Company
Venue:
Georgia World Congress Center
285 Andrew Young International Blvd., NW
Atlanta, Georgia 30313-1591
Map
Contact Information:
Connie Ness
Email: connie.ness@scotent.co.uk
Telephone: 0141 228 2560